Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur P Staddon

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
The Lancet. Oncology|April 13, 2015
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trialJean-Yves Blay, Zsuzsanna Pápai, Anthony W Tolcher, et al.
Cancer|December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcomaScott M Schuetze, J Kyle Wathen, David R Lucas, et al.
JAMA Oncology|May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to ImatinibScott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
Cancer|May 7, 2014
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration studyAlberto S Pappo, Gilles Vassal, John J Crowley, et al.
Cancer|October 4, 2016
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumorScott M Schuetze, Vanessa Bolejack, Edwin Choy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapyGeorge D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.
Lancet (London, England)|May 19, 2012
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T A van der Graaf, Jean-Yves Blay, Sant P Chawla, et al.
The New England Journal of Medicine|July 30, 2015
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorWilliam D Tap, Zev A Wainberg, Stephen P Anthony, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
The Lancet. Oncology|April 13, 2015
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trialJean-Yves Blay, Zsuzsanna Pápai, Anthony W Tolcher, et al.
Cancer|December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcomaScott M Schuetze, J Kyle Wathen, David R Lucas, et al.
JAMA Oncology|May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to ImatinibScott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
Cancer|May 7, 2014
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration studyAlberto S Pappo, Gilles Vassal, John J Crowley, et al.
Cancer|October 4, 2016
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumorScott M Schuetze, Vanessa Bolejack, Edwin Choy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapyGeorge D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.
Lancet (London, England)|May 19, 2012
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T A van der Graaf, Jean-Yves Blay, Sant P Chawla, et al.
The New England Journal of Medicine|July 30, 2015
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorWilliam D Tap, Zev A Wainberg, Stephen P Anthony, et al.
Pageof 2